News for Healthier Living

KRICT-Canaph-Oscotec Advance OCT-598 into Clinic, Setting a Model for Public-Private Drug Development

Korea Research Institute of Chemical Technology (KRICT), in collaboration with Canaph Therapeutics, and with clinical development led by Oscotec Inc., announced that the novel anticancer drug candidate OCT-598 (a dual EP2/EP4 inhibitor) has successfully entered the clinical development phase, marking a major milestone in Korea's public-private drug development collaboration model.

January 28, 2026


January 28 2026

January 27 2026

January 26 2026

January 25 2026

January 24 2026

January 23 2026

January 22 2026

January 21 2026

January 20 2026

January 19 2026

January 18 2026

January 17 2026

January 16 2026

January 15 2026

January 14 2026